Cover Image
市場調查報告書

伊波拉病毒感染(伊波拉出血熱):開發中產品分析

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 398831
出版日期 內容資訊 英文 264 Pages
訂單完成後即時交付
價格
Back to Top
伊波拉病毒感染(伊波拉出血熱):開發中產品分析 Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 264 Pages
簡介

伊波拉是一種罕見但致命的病毒感染,會導致身體內外的出血。症候包括有發熱,嚴重頭痛,關節和肌肉疼痛,喉嚨痛,噁心和嘔吐,腹瀉,胸痛和咳嗽。支持治療包括氧氣療法,輸血,靜脈注射液和止痛藥。

本報告提供伊波拉病毒感染 (伊波拉出血熱)的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊

簡介

  • 調查範圍

E伊波拉病毒感染(伊波拉出血熱) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/研究機關研究中的產品

開發治療藥的企業

  • Abivax SA
  • AnGes MG Inc
  • ANP Technologies Inc
  • Arno Therapeutics Inc
  • BioCryst Pharmaceuticals Inc
  • BioFactura Inc
  • Celgene Corp
  • Emergent BioSolutions Inc
  • Enyo Pharma SAS
  • Etubics Corp
  • GeoVax Labs Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Hemispherx Biopharma Inc
  • Humabs BioMed SA
  • Immune Response BioPharma Inc
  • Immunovaccine Inc
  • Inovio Pharmaceuticals Inc
  • Integrated BioTherapeutics Inc
  • Johnson & Johnson
  • Kineta Inc
  • Kymab Ltd
  • Medicago Inc
  • Merck & Co Inc
  • Microbiotix Inc
  • Micropharm Ltd
  • NanoViricides Inc
  • Navigen Pharmaceuticals, Inc.
  • Novavax Inc
  • Peregrine Pharmaceuticals Inc
  • Phelix Therapeutics LLC
  • PlantForm Corp
  • Profectus BioSciences Inc
  • RedHill Biopharma Ltd
  • Regeneron Pharmaceuticals Inc
  • Rodos BioTarget GmbH
  • SignPath Pharma Inc
  • Sirnaomics Inc
  • Soligenix Inc
  • Taiga Biotechnologies Inc
  • Tamir Biotechnology Inc
  • TGV-Laboratories
  • 富山化學工業
  • Vaxart Inc
  • XBiotech Inc

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9682IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4, 8, 47 and 26 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 5 molecules, respectively.

Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Overview
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Development
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Assessment
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Companies Involved in Therapeutics Development
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drug Profiles
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Abivax SA, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Adimab LLC, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Akshaya Bio Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by AnGes MG Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Arno Therapeutics Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Atreca Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by BioFactura Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Cadila Healthcare Ltd, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Celgene Corp, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Cocrystal Pharma Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Enyo Pharma SA, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Fab'entech SA, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Fujifilm Holdings Corporation, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Gilead Sciences Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Globavir Biosciences Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Hemispherx Biopharma Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Humabs BioMed SA, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Immune Response BioPharma Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Immunovaccine Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Integrated BioTherapeutics Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Johnson & Johnson, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Kineta Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Medicago Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Merck & Co Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Microbiotix Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Micropharm Ltd, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by NanoViricides Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Navigen Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Novavax Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Peregrine Pharmaceuticals Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Phelix Therapeutics LLC, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by PlantForm Corp, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by RedHill Biopharma Ltd, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Rodos BioTarget GmbH, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by SignPath Pharma Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Sirnaomics Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Soligenix Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Taiga Biotechnologies Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Tamir Biotechnology Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Theravectys SA, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by Vaccibody AS, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Pipeline by XBiotech Inc, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Top 10 Routes of Administration, H2 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top